Supplementary Table 1. si*SRA* sequences used in the present study.

No	siRNA		Duplex sequence	MW
1	*SRA1*	Sense	5’ CUCAUAACAUGCAUUUCAAUU 3’	6227
		Antisense	5’ UUGAAAUGCAUGUUAUGAGUU 3’	6364.1
2	*SRA2*	Sense	5’ GCUCAAGUGAGACACUUAAUU 3’	6345.1
		Antisense	5’ UUAAGUGUCUCACUUGAGCUU 3’	6276
3	*SRA3*	Sense	5’ ACGUGAAUGUGGAGAUUGUUU 3’	6419.2.1
		Antisense	5’ ACAAUCUCCACAUUCACGUUU 3’	6202
4	*SRA4*	Sense	5’ CAAGGAAGCAGGUAUGUGAUU 3’	6464.2
		Antisense	5’ UCACAUACCUGCUUCCUUGUU 3’	6171.9
5	*SRA5*	Sense	5’ GUCCUAUUUGCACUGUAUCUU 3’	6212.9
		Antisense	5’ GAUACAGUGCAAAUAGGACUU 3’	6408.2
6	*SRA6*	Sense	5’ CUGUAUCACCCUUGAGAUAUU 3’	6259
		Antisense	5’ UAUCUCAAGGGUGAUACAGUU 3’	6362.1

Supplementary Table 2. siEIF4E-BP1 sequences used in the present study.

No	siRNA		Duplex sequence	MW
1	EIF4E-BP1_1	Sense	5’ GCAAUAGCCCAGAAGAUAAUU 3’	6391.2
		Antisense	5’ UUAUCUUCUGGGCUAUUGCUU 3’	6229.9
2	EIF4E-BP1_2	Sense	5’ GUUUGAGAUGGACAUUUAAUU 3’	6364.1
		Antisense	5’ UUAAAUGUCCAUCUCAAACUU 3’	6227

Supplementary Table 3. Primer sequences used in the present study.

Gene	Primer sequence		Product size (bp)
	Forward (5'-3')	Reverse (5'-3')	
SRA	CTCCCTTCTTACCACCACCA	TGCAGATACACAGGGAGCAG	217
β-catenin,	TGCAGTTCGCCTTCACTATG	ACTAGTCGTGGAATGGCACC	162
Gsk-3β	AACTGCCCGACTAACACCAC	ATTGGTCTGTCCACGGTCTC	154
c-Myc	GGACGACGAGACCTTCATCAA	CCAGCTTCTCTCAGACGAGCTT	92

[i] SRA, steroid receptor RNA activator.


A
ECC-1
Relative SRA4 expression
1.2
1
0.8
0.6
0.4
0.2
0
*
***
***
***
***
***
***
Control
siNC
siSRA1
siSRA2
siSRA3
siSRA4
siSRA5
siSRA6
B
Control
siNC
siSRA1
siSRA2
siSRA3
siSRA4
siSRA5
siSRA6
0h
24h
48h
ECC-1
Migration (%)
120
100
80
60
40
20
0
0h
24h
48h
Time (h)
Control
siNC
siSRA1
siSRA2
siSRA3
siSRA4
siSRA5
siSRA6
C
ECC-1
Control
siNC
siSRA1
siSRA3
siSRA5
siSRA6
ECC-1
Number of Individual cells (fold change)
200
150
100
50
0
**
*
*
**
Control
siNC
siSRA1
siSRA3
siSRA5
siSRA6

Supplementary Figure. 1. Knockdown of *SRA* inhibits endometrial cancer *SRA* expression, migration, and invasion to minimize the possibility of off-target effects. (A) Knockdown efficiency was determined by qRT-PCR analysis in ECC-1 cells. Cells were transfected with *SRA* siRNA (si*SRA*) or negative control siRNA (siNC and Control). (B) Wound healing assay was used to determine migration in *SRA*-specific siRNA (si*SRA*)-transfected ECC-1 cells (×200). (C) Matrigel invasion assay was used to determine invasion after 48 h in si*SRA* transfected ECC-1 cells. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. *$p < 0.05$, **$p < 0.01$, and ***$p < 0.001$ vs. siNC.


A
ECC-1
Relative EIF4E-BP1 expression
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
Ishikawa
Relative EIF4E-BP1 expression
1.2
1
0.8
0.6
0.4
0.2
0
***
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
B
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
0h
24h
48h
ECC-1
Migration (%)
25
20
15
10
5
0
0h
24h
48h
Time (h)
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
0h
24h
48h
Ishikawa
Migration (%)
50
40
30
20
10
0
0h
24h
48h
Time (h)
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
C
ECC-1
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
ECC-1
Number of Individual cells (fold change)
200
150
100
50
0
***
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
Ishikawa
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2
Ishikawa
Number of Individual cells (fold change)
700
600
500
400
300
200
100
0
*
Control
siNC
siEIF4EBP1_1
siEIF4EBP1_2

Supplementary Figure. 2. Knockdown of EIF4E-BP1 inhibits endometrial cancer EIF4E-BP1 expression, migration, and invasion to minimize the possibility of off-target effects. (A) Knockdown efficiency was determined by qRT-PCR analysis in ECC-1 and Ishikawa cells. Cells were transfected with EIF4E-BP1 siRNA (siEIF4E-BP1) or negative control siRNA (siNC and Control). (B) Wound healing assay was used to determine migration in EIF4E-BP1-specific siRNA (siEIF4E-BP1)-transfected ECC-1 and Ishikawa cells (×200). (C) Matrigel invasion assay was used to determine invasion after 48 h in siEIF4E-BP1 transfected ECC-1 and Ishikawa cells. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. $*p < 0.05$, $**p < 0.01$, and $***p < 0.001$ vs. siNC and Control.